硫酸镁联合拉贝洛尔治疗妊娠高血压综合征的临床效果及对血浆和红细胞内钙、镁离子浓度的影响
|
摘要
目的探讨硫酸镁联合拉贝洛尔治疗妊娠高血压综合征(PIHS)的临床效果及其对患者血浆和红细胞内钙、镁离子浓度的影响。方法将我院收治的96例PIHS患者按随机抽签原则分为参照组与试验组,各48例。两组均给予基础治疗措施,在此基础上参照组给予硫酸镁治疗,试验组给予硫酸镁联合拉贝洛尔治疗。比较两组治疗前、后血压控制效果、血浆和红细胞内钙、镁离子浓度、血液相关指标水平、临床疗效及不良反应发生情况。结果治疗前,两组患者血压(收缩压、舒张压)、血浆和红细胞内钙、镁离子浓度均无显著差异(P>0.05)。治疗后,两组患者血压(收缩压、舒张压)均降低,且试验组低于参照组(P<0.05);两组患者血浆钙离子、血浆镁离子及红细胞镁离子浓度均显著升高,且试验组高于参照组(P<0.05)。试验组治疗总有效率高于参照组(P<0.05)。治疗前,两组患者VEGF、GMP-140水平、PT及APTT无显著差异(P>0.05);治疗后,两组患者VEGF水平升高,PT及APTT延长,GMP-140水平降低,且试验组优于参照组(P<0.05)。试验组不良反应总发生率低于参照组(P<0.05)。结论硫酸镁联合拉贝洛尔治疗PIHS效果显著,可有效控制患者血压,调节机体钙、镁离子紊乱,改善血液高凝状态,减少不良反应发生情况。
Objective To investigate the clinical effect of magnesium sulfate combined with labetalol in the treatment of pregnancy induced hypertension syndrome(PIHS) and its influence on the concentration of calcium and magnesium ions in plasma and erythrocyte. Methods Ninety-six PIHS patients admitted in our hospital were divided into reference group and experimental group according to the principle of random lottery, with 48 cases in each group. Both groups were given basic treatment measures, on this basis, the reference group was given magnesium sulfate treatment, and the experimental group was given magnesium sulfate combined with labetalol treatment. The effects of blood pressure control, the concentration of calcium and magnesium ions in plasma and erythrocyte, the levels of blood related indicators before and after treatment, the clinical efficacy and adverse reactions were compared between the two groups. Results Before treatment, there were no significant differences in blood pressure(systolic and diastolic blood pressure), plasma and erythrocyte calcium and magnesium ions concentrations between the two groups(P>0.05). After treatment, the blood pressure(systolic and diastolic blood pressure) of both groups decreased, and those in the experimental group were lower than the reference group(P <0.05); the plasma calcium ion, plasma magnesium ion and erythrocyte magnesium ion concentrations of the two groups increased significantly, and those in the experimental group were higher than the reference group(P <0.05). The total effective rate of treatment in the experimental group was higher than that in the reference group(P<0.05). Before treatment,there were no significant differences in the levels of VEGF, GMP-140, PT and APTT between the two groups(P>0.05).After treatment, the levels of VEGF increased and PT and APTT prolonged in the two groups, and the levels of GMP-140 decreased in the two groups, and those in the experimental group were better than the reference group( P <0.05). The total incidence of adverse reactions in the experimental group was lower than that in the reference group( P <0.05).Conclusion Magnesium sulfate combined with labetalol in the treatment of PIHS has a remarkable effect, which can effectively control blood pressure, regulate the disorder of calcium and magnesium ions, improve blood hypercoagulability and reduce the occurrence of adverse reactions.
Objective To investigate the clinical effect of magnesium sulfate combined with labetalol in the treatment of pregnancy induced hypertension syndrome(PIHS) and its influence on the concentration of calcium and magnesium ions in plasma and erythrocyte. Methods Ninety-six PIHS patients admitted in our hospital were divided into reference group and experimental group according to the principle of random lottery, with 48 cases in each group. Both groups were given basic treatment measures, on this basis, the reference group was given magnesium sulfate treatment, and the experimental group was given magnesium sulfate combined with labetalol treatment. The effects of blood pressure control, the concentration of calcium and magnesium ions in plasma and erythrocyte, the levels of blood related indicators before and after treatment, the clinical efficacy and adverse reactions were compared between the two groups. Results Before treatment, there were no significant differences in blood pressure(systolic and diastolic blood pressure), plasma and erythrocyte calcium and magnesium ions concentrations between the two groups(P>0.05). After treatment, the blood pressure(systolic and diastolic blood pressure) of both groups decreased, and those in the experimental group were lower than the reference group(P <0.05); the plasma calcium ion, plasma magnesium ion and erythrocyte magnesium ion concentrations of the two groups increased significantly, and those in the experimental group were higher than the reference group(P <0.05). The total effective rate of treatment in the experimental group was higher than that in the reference group(P<0.05). Before treatment,there were no significant differences in the levels of VEGF, GMP-140, PT and APTT between the two groups(P>0.05).After treatment, the levels of VEGF increased and PT and APTT prolonged in the two groups, and the levels of GMP-140 decreased in the two groups, and those in the experimental group were better than the reference group( P <0.05). The total incidence of adverse reactions in the experimental group was lower than that in the reference group( P <0.05).Conclusion Magnesium sulfate combined with labetalol in the treatment of PIHS has a remarkable effect, which can effectively control blood pressure, regulate the disorder of calcium and magnesium ions, improve blood hypercoagulability and reduce the occurrence of adverse reactions.
引文
[1]葛新梅,谷强.妊娠高血压综合征发病机制及防治的研究进展[J].医学综述,2013,19(7):1270-1272.
[2]程凤英,邢秀霜,许武凤,等.硫酸镁对妊娠高血压患者血浆和红细胞内钙、镁离子的浓度变化及其机制分析[J].中国地方病防治杂志,2017,32(11):1280.
[3]平燕,董尚妹.硫酸镁联合拉贝洛尔治疗妊娠高血压综合征的临床效果及血浆和红细胞内钙、镁离子的浓度变化分析[J].中国医学前沿杂志:电子版,2017,9(1):139-142.
[4]王曼,俞瑾,钱祖淇.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准[J].中国中西医结合杂志,1991,11(6):376-379.
[5]颜智.硫酸镁联合硝苯地平治疗妊娠高血压综合征的临床研究[J].临床医学工程,2016,23(2):199-200.
[6]徐嵘.硫酸镁联合拉贝洛尔治疗对重症妊娠期高血压患者血压、血清同型半胱氨酸及C-反应蛋白水平的影响[J].中国妇幼保健,2018,33(5):1028-1030.
[7]彭李珍,张晓黔,陈雪群,等.硫酸镁对妊娠高血压病患者血浆和红细胞内钙、镁离子影响[J].牡丹江医学院学报,2016,37(2):63-64.
[8]钱小泉,宋艳萍,王丽琴,等.血管内皮生长因子和缺氧诱导因子-1α在妊娠高血压综合征患者胎盘组织中的表达[J].生殖与避孕,2014,34(8):628-632.
[9]吴怡,代维栋,符乔珊.LRRFIP1在妊娠期高血压疾病患者血清中的表达及临床意义[J].中国妇幼健康研究,2018,29(5):625-628.
[10]华杰.妊娠期高血压疾病患者凝血功能及抗氧化能力的变化及临床意义[J].中国妇幼保健,2016,31(2):266-268.
[11]马竹云,张宝艳.硫酸镁联合拉贝洛尔治疗对早发型重度子痫前期孕妇血压、心率及血流动力学指标的影响[J].中国妇幼保健,2018,33(10):2189-2191.
[12]郝海燕.拉贝洛尔联合硫酸镁治疗妊娠高血压的效果观察[J].河南医学研究,2018,27(20):3732-3733.
[2]程凤英,邢秀霜,许武凤,等.硫酸镁对妊娠高血压患者血浆和红细胞内钙、镁离子的浓度变化及其机制分析[J].中国地方病防治杂志,2017,32(11):1280.
[3]平燕,董尚妹.硫酸镁联合拉贝洛尔治疗妊娠高血压综合征的临床效果及血浆和红细胞内钙、镁离子的浓度变化分析[J].中国医学前沿杂志:电子版,2017,9(1):139-142.
[4]王曼,俞瑾,钱祖淇.子宫内膜异位症、妊娠高血压综合征及女性不孕症的中西医结合诊疗标准[J].中国中西医结合杂志,1991,11(6):376-379.
[5]颜智.硫酸镁联合硝苯地平治疗妊娠高血压综合征的临床研究[J].临床医学工程,2016,23(2):199-200.
[6]徐嵘.硫酸镁联合拉贝洛尔治疗对重症妊娠期高血压患者血压、血清同型半胱氨酸及C-反应蛋白水平的影响[J].中国妇幼保健,2018,33(5):1028-1030.
[7]彭李珍,张晓黔,陈雪群,等.硫酸镁对妊娠高血压病患者血浆和红细胞内钙、镁离子影响[J].牡丹江医学院学报,2016,37(2):63-64.
[8]钱小泉,宋艳萍,王丽琴,等.血管内皮生长因子和缺氧诱导因子-1α在妊娠高血压综合征患者胎盘组织中的表达[J].生殖与避孕,2014,34(8):628-632.
[9]吴怡,代维栋,符乔珊.LRRFIP1在妊娠期高血压疾病患者血清中的表达及临床意义[J].中国妇幼健康研究,2018,29(5):625-628.
[10]华杰.妊娠期高血压疾病患者凝血功能及抗氧化能力的变化及临床意义[J].中国妇幼保健,2016,31(2):266-268.
[11]马竹云,张宝艳.硫酸镁联合拉贝洛尔治疗对早发型重度子痫前期孕妇血压、心率及血流动力学指标的影响[J].中国妇幼保健,2018,33(10):2189-2191.
[12]郝海燕.拉贝洛尔联合硫酸镁治疗妊娠高血压的效果观察[J].河南医学研究,2018,27(20):3732-3733.